Impact of the Navilas ® Micropulse Laser Treatment for Macular Edema Within the CHU Brugmann Hospital Macular Edema

CHU Brugmann University Hospital

Status: Completed

Conditions: Macular Edema

Treatments: Other: Data extraction from medical files

Study type: Observational

Funder types: Other

Identifiers

NCT04857099

CHUB-Kemani

Details and patient eligibility

About

The Navilas® micropulse laser can be used to treat patients with macular edema and good visual acuity, which therefore do not fall within the indications for conventional treatments by intravitreal injections.

The CHU Brugmann Hospital is the only center to own this laser in Belgium.This study aims to evaluate the efficacy of this laser.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diffuse macular edema without focal edema source accessible by focal laser (e.g. capillary telangiectasia)
• Central retinal thickness ≤ 400microns.
• Patient does not meet the reimbursement criteria for intra-vitreous injections(IVI) of anti-VEGF (eg AV> 5/10).
• IVI are contraindicated.
• Physician considers that it is preferable to space out the injections because of the side effects (eg. ocular disturbance during IVI, eye pain, sensation of a foreign body, spots in the visual field generating a visual gene etc.)
• Patient wishing to space the anti-VEGF IVI.

Exclusion criteria

• Macular edema of a different etiology than diabetic macular edema or venous thrombosis (e.g. cataract extraction, vitreomacular traction, epiretinal membrane etc.)
• Central retinal thickness > 400 microns.
• The eye presents a focal edematous maculopathy accessible to conventional laser.

Trial design

23 participants in 1 patient group

Macular edema

Treatment:

Other: Data extraction from medical files